Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 16.30 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-03
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 16.30K shares, a 83.75% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 6.35K shares, a 154.00% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 13.85K shares, a 65.94% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 16.30K shares, a 97.02% decline from fiscal 2024.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 547.45K shares, a 35.21% increase from fiscal 2023.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 404.90K shares, a 26.89% decline from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 553.83K shares, a 4.59% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 16.30K shares 10-K · filed 2026-03-03 | ||||
| 2025-06-30 | 16.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-05 | 16.30K shares 10-Q · filed 2025-11-05 | 11.30K shares 10-Q · filed 2025-07-30 | 22.65K shares derived: sum of 3 quarters · filed 2025-11-05 | 36.50K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 6.35K shares derived: sum of 2 quarters · filed 2025-05-09 | 20.20K shares derived: sum of 3 quarters · filed 2025-05-09 | 120.53K shares derived: sum of 4 quarters · filed 2025-05-09 | |
| 2024-12-31 | 6.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 20.20K shares derived: sum of 2 quarters · filed 2025-03-17 | 120.53K shares derived: sum of 3 quarters · filed 2025-03-17 | 547.45K shares 10-K · filed 2025-03-17 | |
| 2024-09-30 | 13.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 114.17K shares derived: sum of 2 quarters · filed 2024-11-04 | 541.10K shares 10-Q · filed 2024-11-04 | 543.60K shares derived: sum of 4 quarters · filed 2024-11-04 | |
| 2024-06-30 | 100.33K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 527.25K shares 10-Q · filed 2024-08-08 | 529.75K shares derived: sum of 3 quarters · filed 2024-08-08 | 570.41K shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 426.93K shares 10-Q · filed 2024-05-08 | 429.43K shares derived: sum of 2 quarters · filed 2024-05-08 | 470.08K shares derived: sum of 3 quarters · filed 2024-05-08 | 492.68K shares derived: sum of 4 quarters · filed 2024-05-08 | |
| 2023-12-31 | 2.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 43.16K shares derived: sum of 2 quarters · filed 2024-03-15 | 65.76K shares derived: sum of 3 quarters · filed 2024-03-15 | 404.90K shares 10-K · filed 2024-03-15 | |
| 2023-09-30 | 40.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 63.26K shares derived: sum of 2 quarters · filed 2023-11-03 | 402.40K shares 10-Q · filed 2023-11-03 | 469.33K shares derived: sum of 4 quarters · filed 2023-11-03 | |
| 2023-06-30 | 22.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 361.75K shares 10-Q · filed 2023-08-08 | 428.67K shares derived: sum of 3 quarters · filed 2023-08-08 | 450.80K shares derived: sum of 4 quarters · filed 2023-08-08 | |
| 2023-03-31 | 339.14K shares 10-Q · filed 2023-05-09 | 406.07K shares derived: sum of 2 quarters · filed 2023-05-09 | 428.20K shares derived: sum of 3 quarters · filed 2023-05-09 | 476.77K shares derived: sum of 4 quarters · filed 2023-05-09 | |
| 2022-12-31 | 66.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 89.05K shares derived: sum of 2 quarters · filed 2023-03-16 | 137.63K shares derived: sum of 3 quarters · filed 2023-03-16 | 553.83K shares 10-K · filed 2023-03-16 | |
| 2022-09-30 | 22.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 70.70K shares derived: sum of 2 quarters · filed 2022-11-09 | 486.90K shares 10-Q · filed 2022-11-09 | 522.78K shares derived: sum of 4 quarters · filed 2022-11-09 | |
| 2022-06-30 | 48.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 464.77K shares 10-Q · filed 2022-08-04 | 500.65K shares derived: sum of 3 quarters · filed 2022-08-04 | ||
| 2022-03-31 | 416.20K shares 10-Q · filed 2022-05-06 | 452.07K shares derived: sum of 2 quarters · filed 2022-05-06 | |||
| 2021-12-31 | 35.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 529.50K shares 10-K · filed 2022-03-11 | |||
| 2021-09-30 | 493.63K shares 10-Q · filed 2021-11-05 | ||||
| 2015-06-30 | 7.50K shares 10-Q · filed 2015-08-04 | 111.63K shares 10-Q · filed 2015-08-04 | |||
| 2015-03-31 | 104.13K shares 10-Q · filed 2015-05-04 | ||||
| 2014-09-30 | 7.00K shares 10-Q · filed 2014-11-06 | 16.00K shares derived: sum of 2 quarters · filed 2014-11-06 | 139.24K shares 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | 9.00K shares 10-Q · filed 2014-08-04 | 132.24K shares 10-Q · filed 2014-08-04 | |||
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | 20.00K shares derived: sum of 2 quarters · filed 2013-11-05 | 374.50K shares 10-Q · filed 2013-11-05 | ||
| 2013-06-30 | 20.00K shares 10-Q · filed 2013-08-06 | 374.50K shares 10-Q · filed 2013-08-06 | |||
| 2013-03-31 | 354.50K shares 10-Q · filed 2013-05-06 | ||||
| 2012-09-30 | 75.00K shares 10-Q · filed 2012-11-08 | 194.00K shares 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | 119.00K shares 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |